Holen Sie sich die Stockscreener-App
29.51
1.24%
-0.37
Handel nachbörslich:
29.51
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Insider Sell: Does Celldex Therapeutics Inc stock benefit from AI growth2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria - Sahm
Chronic Spontaneous Urticaria Pipeline Expands with 25+ - openPR.com
CLDX: Barzolvolimab shows strong efficacy in CSU, with key phase 3 data expected in Q4 - TradingView
Celldex Therapeutics stock hits 52-week high at $31.36 By Investing.com - Investing.com South Africa
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month HighStill a Buy? - MarketBeat
Celldex Therapeutics stock hits 52-week high at $31.36 - Investing.com India
Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference - MarketBeat
A Look At Celldex Therapeutics (CLDX) Valuation After New Barzolvolimab Urticaria Data - Sahm
Fund Flows: Can Celldex Therapeutics Inc keep up with sector leadersJuly 2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Market Outlook: Will Celldex Therapeutics Inc benefit from geopolitical trends2025 Dividend Review & Precise Swing Trade Alerts - baoquankhu1.vn
New Barzolvolimab Urticaria Data And Losses Might Change The Case For Investing In Celldex Therapeutics (CLDX) - Sahm
TD Asset Management Inc Decreases Stake in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Propel Bio Management LLC Makes New $4.01 Million Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Volatility Watch: Will Celldex Therapeutics Inc benefit from government policyTrade Performance Summary & High Conviction Buy Zone Picks - baoquankhu1.vn
Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Fisher Asset Management LLC Acquires 104,949 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Exploring an 83.57% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
The Goldman Sachs Group Increases Celldex Therapeutics (NASDAQ:CLDX) Price Target to $34.00 - MarketBeat
Q3 Earnings Forecast for CLDX Issued By HC Wainwright - MarketBeat
Celldex Presents Positive Data Demonstrating Barzolvolimab - GlobeNewswire
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Dis - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory - Insider Monkey
Assessing Celldex Therapeutics (CLDX) Valuation After Positive Barzolvolimab Phase 3 Enrollment And Phase 2 Data - simplywall.st
Celldex Stock Pre-Market (-4.7%): Profit-Taking After Positive Phase 2 Data Presentation - Trefis
Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential - Yahoo Finance
Celldex presents phase 2 data for chronic urticaria treatment By Investing.com - Investing.com Canada
Celldex Presents Additional Positive Data from Phase 2 - GlobeNewswire
What is HC Wainwright's Forecast for CLDX Q1 Earnings? - MarketBeat
CLDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results - MarketBeat
Celldex Therapeutics Rallied 24% After Clinical Update: Here’s What Analysts See Next - TIKR.com
Celldex Therapeutics stock earns 88 RS rating - MSN
Celldex Therapeutics Hits Day High with 24% Surge in Stock Price - Markets Mojo
Celldex Therapeutics Hits New 52-Week High at $31.00 - Markets Mojo
Celldex Therapeutics stock hits 52-week high at 30.66 USD By Investing.com - Investing.com India
November 20th Options Now Available For Celldex Therapeutics (CLDX) - Nasdaq
Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from Stifel Nicolaus - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Hits New 52-Week HighHere's What Happened - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CLDX Technical Analysis & ETF Price Forecast - Intellectia AI
CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent - Stocktwits
Celldex Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Celldex: Fourth Quarter Financial Overview - Bitget
Celldex: Q4 Earnings Snapshot - marketscreener.com
Celldex Therapeutics stock hits 52-week high at 30.66 USD - Investing.com
Celldex Therapeutics Opens with a 6.56% Gain, Outpacing S&P 500's 0.69% Increase - Markets Mojo
Celldex Therapeutics, Inc. SEC 10-K Report - TradingView
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics Hits Day High with Strong 7.91% Intraday Surge - Markets Mojo
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q4 Revenue $0.1M, vs. FactSet Est of $1.3M - marketscreener.com
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Celldex Therapeutics Completes Enrollment in Phase 3 Studies of Barzolvolimab; Shares Rise - marketscreener.com
Celldex surges after completing enrollments in late-stage trials for lead asset - Seeking Alpha
Celldex Therapeutics Completes Enrollment in Phase 3 Studies of Barzolvolimab in Chronic Spontaneous Urticaria - marketscreener.com
Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria - marketscreener.com
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule - Investing.com Canada
Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria. - Bitget
Celldex completes enrollment in global Phase 3 studies (Embarq-Csu1 and Embarq-Csu2) of barzolvolimab in chronic spontaneous urticaria - marketscreener.com
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria - Yahoo Finance
Earnings Update: Will FTB PRACL benefit from sector rotationWeekly Market Summary & Expert Approved Trade Ideas - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):